RTsafe and ZAP Surgical Forge Strategic Partnership to Promote the Latest Advances in Cranial Radiosurgery

RTsafe Partnership Details

RTsafe, the leading provider of quality assurance products and services in stereotactic radiosurgery, and ZAP Surgical, the developer of the ZAP-X® Gyroscopic Radiosurgery® platform, have announced a partnership to promote advances in cranial radiosurgery. Under the terms of the agreement, RTsafe’s dosimetry phantom based on true-to-life human anatomy will be seamlessly integrated into ZAP Surgical’s existing and future global installations. This strategic alliance underscores a shared commitment to excellence, as both organizations strive to deliver optimal patient safety and value to healthcare providers and cranial radiosurgery patients alike.

The cornerstone of this partnership lies in RTsafe’s development of a specialized phantom designed specifically for use with the ZAP-X® platform that incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. This new RTsafe phantom will be officially presented at the International Stereotactic Radiosurgery Society 2024 meeting, in New York City, on May 12th. This innovative solution will play a pivotal role in commissioning, training, educational initiatives, confidence building, periodic quality assurance protocols, and patient-specific quality assurance, reinforcing the state-of-the-art capabilities of ZAP-X.

Evangelos Pappas, Founder of RTsafe

“We are thrilled to join forces with ZAP Surgical in this transformative endeavour. By harnessing the power of our advanced phantom technology, we aim to elevate the standard of care in cranial radiosurgery and to highlight the unparalleled value of the ZAP-X platform”.

Renowned neurosurgeon and Founder of ZAP Surgical, Dr. John Adler

“At ZAP Surgical, we are dedicated to pushing the boundaries of innovation in the field of radiosurgery. By integrating RTsafe’s cutting-edge phantom technology into our systems, we are reinforcing our commitment to excellence and ensuring that clinicians worldwide have access to the most advanced tools for delivering exceptional patient care.” The collaboration between RTsafe and ZAP Surgical is a testament to the power of innovation and collaboration in healthcare.

SourceRTsafe

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.